| BMP4 Protein |
|---|
| Protein Name | Bone Morphogenetic Protein 4 |
| Gene | [BMP4](/entities/bmp4-gene) |
| UniProt ID | [P12644](https://www.uniprot.org/uniprot/P12644) |
| PDB IDs | 3BMP, 1REW |
| Molecular Weight | ~47 kDa (prepro); ~13 kDa (mature monomer); ~26 kDa (active dimer) |
| Subcellular Localization | Secreted; extracellular matrix-associated |
| Protein Family | TGF-β superfamily, BMP subfamily |
| Signaling Type | Paracrine/autocrine growth factor |
Bone Morphogenetic Protein 4 (BMP4) is a secreted signaling molecule of the TGF-β superfamily that plays critical roles in neural development, astrocyte differentiation, and adult brain homeostasis. First identified for its ability to induce ectopic bone formation, BMP4 is now recognized as one of the most important morphogens in nervous system patterning — it establishes dorsal-ventral identity in the neural tube, regulates neural crest cell specification, controls the balance between neurogenesis and gliogenesis, and modulates neural stem cell quiescence in the adult brain.
In the context of neurodegeneration, BMP4 signaling is dysregulated in multiple diseases. BMP4 is upregulated in reactive astrocytes surrounding amyloid plaques in Alzheimer's disease, where it drives astrocytic hypertrophy and inhibits neurogenesis in the hippocampal subgranular zone. In Parkinson's disease, BMP4 promotes astrocyte differentiation at the expense of dopaminergic neuron generation from neural stem cells. Conversely, BMP4 signaling can be neuroprotective by suppressing inflammatory microglial activation and promoting oligodendrocyte maturation in demyelinating conditions.
¶ Biosynthesis and Processing
BMP4 is synthesized as a 408-amino-acid prepropeptide that undergoes sequential processing:
- Signal peptide removal (residues 1–23): Targets BMP4 to the secretory pathway
- Prodomain cleavage: Furin-like proprotein convertases cleave at two sites — an initial cleavage at R256 followed by a second cleavage at R292 — releasing the C-terminal mature domain
- Dimerization: The mature 116-amino-acid monomer forms a disulfide-linked homodimer (the biologically active form) through an intermolecular disulfide bond at C82
The mature BMP4 monomer adopts the characteristic TGF-β superfamily cystine knot fold:
- Three intramolecular disulfide bonds form a ring structure (C14–C79, C43–C111, C47–C113) that threads through each other, creating the cystine knot
- One intermolecular disulfide bond (C82–C82') links two monomers in an antiparallel, "hand-in-hand" orientation
- The dimer presents two receptor binding interfaces — each composed of the wrist epitope (type I receptor binding) and the knuckle epitope (type II receptor binding)
BMP4 bioavailability is tightly regulated by secreted antagonists:
- Noggin: High-affinity BMP4 antagonist that blocks both type I and type II receptor binding sites; critical for neural induction (Noggin expression in Spemann organizer)
- Chordin: Binds BMP4 and sequesters it in inactive complexes; cleaved by BMP1/Tolloid metalloproteases to release active BMP4
- Follistatin: Binds BMP4 with moderate affinity; primarily associated with activin inhibition
- Gremlin: BMP antagonist expressed in the CNS; modulates BMP4 signaling in adult neurogenic niches
BMP4 signals through a heteromeric receptor complex:
- BMP4 dimer binds type I receptors (BMPR1A/ALK3 or BMPR1B/ALK6) and type II receptors (BMPR2, ActRIIA, ActRIIB)
- Type II receptor (constitutively active kinase) phosphorylates the type I receptor GS domain
- Activated type I receptor phosphorylates receptor-regulated SMADs (R-SMADs): SMAD1, SMAD5, and SMAD8/9
- Phospho-SMADs 1/5/8 form a complex with SMAD4 (co-SMAD)
- SMAD complex translocates to the nucleus, where it activates transcription of target genes (ID1, ID2, ID3, MSX1, MSX2, GATA2/3)
BMP4 also activates SMAD-independent pathways:
- TAK1-p38 MAPK: Promotes astrocyte differentiation and inflammatory responses
- PI3K-AKT: Promotes cell survival; relevant to neuroprotection
- JNK: Context-dependent; can promote either survival or death
- ERK1/2: Crosstalk with FGF signaling during neural patterning
BMP4 is secreted from the roof plate of the developing neural tube, establishing a dorsal-to-ventral gradient that specifies dorsal cell fates (sensory interneurons, neural crest). This gradient opposes the ventral Sonic Hedgehog (SHH) gradient from the floor plate:
- High BMP4: dorsal interneurons (dI1-dI3)
- Low BMP4: intermediate progenitors
- No BMP4 + high SHH: motor neurons, ventral interneurons
BMP4 at intermediate concentrations (at the neural plate border) induces neural crest cell specification. These cells migrate to form the peripheral nervous system, melanocytes, craniofacial structures, and enteric nervous system.
A pivotal function of BMP4 in the developing and adult brain is promoting the astrocyte fate at the expense of neurogenesis:
- Developmental gliogenic switch: BMP4/SMAD signaling activates GFAP and S100β promoters while repressing proneural genes (Mash1/Ascl1, Ngn1/2)
- Adult neural stem cells: BMP4 in the hippocampal subgranular zone and subventricular zone maintains stem cell quiescence and promotes astrocytic differentiation. Noggin expression in these niches counterbalances BMP4 to permit neurogenesis[^11]
In the postnatal brain, BMP4 has complex effects on oligodendrocytes:
- Inhibits OPC differentiation: BMP4 blocks oligodendrocyte precursor cell differentiation into mature, myelinating oligodendrocytes by maintaining them in an immature state
- Promotes astrocyte trans-differentiation: At high concentrations, BMP4 can redirect committed OPCs toward an astrocyte fate
- Context-dependent myelination effects: Moderate BMP4 promotes myelin maintenance, while excessive BMP4 inhibits remyelination after injury[^12]
BMP4 is significantly upregulated in AD brain, particularly in reactive astrocytes surrounding amyloid plaques:
- Reactive astrogliosis: BMP4 drives GFAP upregulation, process hypertrophy, and proliferation of reactive astrocytes in the peri-plaque environment. The BMP4→SMAD1/5/8→ID1 pathway is a major driver of the A1 reactive astrocyte phenotype
- Neurogenesis impairment: Elevated BMP4 in the hippocampal dentate gyrus suppresses adult neurogenesis, contributing to memory deficits. Noggin infusion or BMP receptor inhibition rescues neurogenesis in APP/PS1 mice
- Amyloid-β interaction: Aβ42 oligomers directly stimulate BMP4 expression in astrocytes via NF-κB signaling, creating a feed-forward loop: Aβ → astrocytic BMP4 → impaired neurogenesis + astrogliosis → reduced Aβ clearance
- APOE-dependent modulation: APOE4 astrocytes produce more BMP4 than APOE3 astrocytes in response to Aβ, potentially explaining the exaggerated gliosis and neurogenesis impairment in APOE4 carriers[^13]
- Dopaminergic neuron specification: BMP4 normally suppresses the dopaminergic fate during midbrain development (SHH + FGF8 + WNT1 promote dopaminergic differentiation; BMP4 opposes this). Dysregulated BMP4 in the aging substantia nigra may impair compensatory neurogenesis
- Cell replacement therapy: Understanding BMP4 inhibition is critical for iPSC-derived dopaminergic neuron protocols; dual SMAD inhibition (LDN193189/SB431542) is the standard method for deriving midbrain floor plate progenitors from pluripotent stem cells[^14]
¶ Multiple Sclerosis and Demyelination
BMP4 is a major barrier to remyelination:
- BMP4 is upregulated in MS lesions, preventing OPC differentiation into myelinating oligodendrocytes
- Noggin, anti-BMP4 antibodies, or small-molecule BMP receptor inhibitors (LDN193189, DMH1) promote remyelination in cuprizone and EAE models
- BMP4 antagonism is being explored as a remyelination therapy[^15]
¶ Stroke and Ischemia
BMP4 expression increases dramatically after ischemic stroke:
- Elevated BMP4 in the peri-infarct zone inhibits neuroblast migration from the SVZ to the injury site
- BMP4 promotes glial scar formation (beneficial for containment, detrimental for regeneration)
- Noggin infusion into the lateral ventricle increases neuroblast migration to the ischemic penumbra[^16]
| Compound |
Target |
Stage |
CNS Application |
| LDN193189 |
BMPR1A/ALK2 kinase |
Research/preclinical |
Promotes remyelination, neurogenesis |
| DMH1 |
BMPR1A/ALK2 kinase |
Research |
Selective BMP inhibitor; promotes OPC differentiation |
| K02288 |
BMPR1A/ALK2/ALK6 kinase |
Research |
Promotes neurogenesis in adult SVZ |
| Dorsomorphin |
BMPR1A/AMPK (non-selective) |
Research |
Original BMP pathway inhibitor; off-target AMPK effects |
| Recombinant Noggin |
BMP4 ligand (extracellular) |
Preclinical |
Rescues neurogenesis in AD models |
- AD neurogenesis rescue: BMP pathway inhibition in the hippocampal niche to restore adult neurogenesis; requires targeted delivery to avoid systemic effects
- Remyelination in MS: Small-molecule BMP receptor inhibitors to overcome BMP4-mediated OPC differentiation block
- Stem cell protocols: Dual SMAD inhibition for efficient neural induction from iPSCs; BMP4 modulation for generating specific neural subtypes
- Stroke recovery: Transient Noggin delivery to promote neuroblast migration to ischemic areas[^17]
- BMPR1A (ALK3): Primary type I receptor for BMP4 in the CNS
- BMPR2: Type II receptor; constitutively active kinase
- SMAD1/5/8: Downstream transcription factor effectors
- SMAD4: Co-SMAD required for nuclear translocation
- Noggin: High-affinity extracellular antagonist
- Chordin: Extracellular BMP4 sequestrant
- ID1/ID2/ID3: Target transcription factors; inhibit bHLH proneural genes
- SHH: Opposing morphogen gradient in neural tube patterning
- BMP1/Tolloid: Metalloprotease that cleaves Chordin to release BMP4